Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ampio Pharmaceuticals Inc Announces Positive Results For Ampion In Osteoarthritis Of The Knee Clinical Trial


Wednesday, 14 Aug 2013 08:00am EDT 

Ampio Pharmaceuticals Inc announced positive results from the SPRING study (clinicaltrials.gov NCT01839331) of Ampion for the treatment of osteoarthritis of the knee (OAK). In this study of 329 patients, patients treated with a single intra-articular injection of Ampion achieved a clinically meaningful reduction in pain. 

Company Quote

3.33
-0.15 -4.31%
22 Sep 2014